Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Glaucoma in perspective

- PMLiVE

Lucid adds to senior leadership team

Shula Sarner and Tanya Goodyear join the med comms agency

Dr. Thomas Blatter has been appointed Vice President, DACH Region

Dr. Thomas Blatter has been appointed VP DACH region to lead Anthill’s activities in the region, effective immediately.

Anthill Agency

- PMLiVE

IMS Health and Quintiles complete merger

Launch global healthcare information and technology specialist QuintilesIMS

- PMLiVE

Another failed trial knocks back AZ’s plan to grow Brilinta

Rests hopes on ongoing diabetes study but looks set to fall short of $3.5bn annual target

Celgene building

Celgene bolsters blood cancer portfolio with $600m EngMab buy

Consolidates position as top company in current multiple myeloma market

- PMLiVE

Reformed Cancer Drugs Fund backs its first drug – AZ’s Tagrisso

Lung cancer treatment will be available to NHS patients while NICE awaits data

- PMLiVE

firstlight bolsters healthcare team

Appoints Grant Fisher and Kristen Barrett

- PMLiVE

Yoshinori Ohsumi wins Nobel Prize in Medicine for autophagy work

Receives the accolade for his discoveries of mechanisms for the cell process

- PMLiVE

Lucid bolsters its senior leadership team

Lucid Group has had a successful summer attracting top talent to its senior leadership team with the appointment of Shula Sarner (Executive Scientific Director) and Tanya Goodyear (Division Director, Immunology).

Lucid Group Communications Limited

ABPI London offices

UK pledges £220m tech fund for life science and university sectors

ABPI says investment will be well received by the pharma industry

- PMLiVE

GSK draws line under Chinese scandal with $20m SEC settlement

Brings corruption investigation to an end with commitment to ongoing remediation reports

AstraZeneca AZ

AZ licenses inflammatory bowel disease drug to Allergan for $1.52bn

Will receive $250m upfront with a further $1.27bn if drug reaches market in two indications

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links